EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY

Stefan Schreiber  ¹     Jean-Frédéric Colombel  ²     Steve Hanauer  ³     William Sandborn  ⁴     Bruce E. Sands  ⁴     Silvio Danese  ⁵     Sang Joon Lee  ⁶     Sung Hyun Kim  ⁶     Yunju Bae  ⁶     Sunhee Lee  ⁶     Seul Gi Lee  ⁶     JoonHo Lee  ⁶     Jong Min Kim  ⁶     Siyoung Yang  ⁶     Jimin Lee  ⁶     Gahee Park  ⁶     Juhyun Lee  ^6    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Northwestern University/ Feinberg School of Medicine, Chicago, IL, United States
⁴ University of California San Diego, La Jolla, United States
⁵ IRCCS San Raffaele Hospital, Milan, Italy
⁶ Celltrion, Inc, Incheon, Korea, Republic of

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)